- Compact style
- Indico style
- Indico style - inline minutes
- Indico style - numbered
- Indico style - numbered + minutes
- Indico Weeks View
There is a live webcast for this event, webcast link: https://webcast.web.cern.ch/event/i1431627
Cancer is a central health problem for our society and is, unfortunately, set to spiral, as cancer cases increase worldwide.
A large fraction of patients treated for cancer receive radiation therapy, most often together with other treatment modalities as a part of a holistic treatment approach. Most cancer radiation treatments, worldwide, are delivered with high-energy X-rays. However, hadron therapy, also known as particle therapy, using protons and heavier ions, is an emerging effective modality that has many advantages. Namely, proton and heavy ion beams can irradiate tumors by focusing precisely on cancerous tissue whilst sparing healthy tissue around it, making the treatment more effective than any other irradiation treatment, and in some cases the only option.
Due to this, the European Union, through its H2020 research and innovation program, is funding the Heavy Ion Therapy Research Integration (HITRIplus) project supporting, technical advancements, transnational acces, networking, dissemination and capacity building in heavy ion therapy research.
Hence, HITRIplus supports a 2-days international Symposium on Hadron Therapy, in Thessaloniki. It will take place on the 18th and 19th of October 2024, in hybrid mode, and is free of charge. Event in conjuction with the IAEA Regional Workshop on Hadron Therapy under the Technical Cooperation project RER6039.
Over 30 world-leading experts in the field participate. They will cover a broad spectrum, from the principles of hadron therapy and radiobiology to experiences of the European running hadron therapy centres and their upgrades plans, including specific indications for hadron therapy such as head and neck, sarcoma and others. Dedicated sessions will address pediatrics as well as emerging methods, such as combinations of hadron therapy with immunotherapy and FLASH therapy, highlighting also unfolding research avenues and the related necessary technical advancements on the accelerator and beam delivery systems.
The presentations will be recorded and made freely available online.